New drug trial aims to ease severe pregnancy complication
NCT ID NCT06333652
First seen Nov 12, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study tests a medication called ravulizumab in pregnant women with severe preeclampsia or HELLP syndrome, serious conditions that can harm both mother and baby. The goal is to see if the drug can improve health markers and extend pregnancy duration. About 14 participants will be enrolled at Mayo Clinic.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREECLAMPSIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-••••
Locations
-
Mayo Clinic Minnesota
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.